ArticlePDF AvailableLiterature Review

The Effects of L-Carnitine, Acetyl-L-Carnitine, and Propionyl-L-Carnitine on Body Mass in Type 2 Diabetes Mellitus Patients

Frontiers
Frontiers in Nutrition
Authors:

Abstract and Figures

Purpose: The study aimed to explore the effects of l-carnitine, acetyl-l-carnitine, and propionyl-l-carnitine on Body Mass in type 2 diabetes mellitus (T2DM) patients. Methods: Randomized controlled trial (RCT) studies of l-carnitine, acetyl-l-carnitine, and propionyl-l-carnitine in T2DM patients were searched. The change rates of Body Mass index (BMI) from baseline values were used as an evaluation indicator. The maximal effect (Emax) model by non-linear mixed-effect modeling (NONMEM) was used as the evaluation method. Results: A total of 10 RCT studies, 1239 T2DM patients were included for analysis, including eight studies of l-carnitine, one study of acetyl-l-carnitine, and one study of propionyl-l-carnitine. The study found that l-carnitine could reduce the Body Mass of T2DM patients. Based on only one study each for acetyl-l-carnitine and propionyl-l-carnitine, no significant effects were found in acetyl-l-carnitine or propionyl-l-carnitine. In addition, in order to achieve a plateau of efficacy (80% Emax), 2 g/day l-carnitine was required for at least 2 weeks. Conclusions: Two g/day l-carnitine was required for at least 2 weeks to affect Body Mass in T2DM patients, and no significant effects were found in acetyl-l-carnitine or propionyl-l-carnitine.
This content is subject to copyright.
SYSTEMATIC REVIEW
published: 08 November 2021
doi: 10.3389/fnut.2021.748075
Frontiers in Nutrition | www.frontiersin.org 1November 2021 | Volume 8 | Article 748075
Edited by:
Clelia Madeddu,
University of Cagliari, Italy
Reviewed by:
Sidney B. Peres,
State University of Maringá, Brazil
Marco Vacante,
University of Catania, Italy
*Correspondence:
Dong-Dong Wang
13852029591@163.com
Su-Mei He
hehe8204@163.com
You-Mei Wang
wym15861703855@163.com
These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Clinical Nutrition,
a section of the journal
Frontiers in Nutrition
Received: 07 August 2021
Accepted: 11 October 2021
Published: 08 November 2021
Citation:
Wang D-D, Wang T-Y, Yang Y, He S-M
and Wang Y-M (2021) The Effects of
L-Carnitine, Acetyl-L-Carnitine, and
Propionyl-L-Carnitine on Body Mass
in Type 2 Diabetes Mellitus Patients.
Front. Nutr. 8:748075.
doi: 10.3389/fnut.2021.748075
The Effects of L-Carnitine,
Acetyl-L-Carnitine, and
Propionyl-L-Carnitine on Body Mass
in Type 2 Diabetes Mellitus Patients
Dong-Dong Wang 1
*, Tian-Yun Wang 2†, Yang Yang 3†, Su-Mei He 4
*and You-Mei Wang 2
*
1Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy & School of Pharmacy, Xuzhou Medical University,
Xuzhou, China, 2Department of Pharmacy, Huaian Hospital of Huaian City, Huaian, China, 3Department of Pharmacy, The
Affiliated Changzhou Children’s Hospital of Nantong University, Changzhou, China, 4Department of Pharmacy, The Affiliated
Suzhou Science & Technology Town Hospital of Nanjing Medical University, Suzhou, China
Purpose: The study aimed to explore the effects of l-carnitine, acetyl-l-carnitine, and
propionyl-l-carnitine on Body Mass in type 2 diabetes mellitus (T2DM) patients.
Methods: Randomized controlled trial (RCT) studies of l-carnitine, acetyl-l-carnitine, and
propionyl-l-carnitine in T2DM patients were searched. The change rates of Body Mass
index (BMI) from baseline values were used as an evaluation indicator. The maximal
effect (Emax) model by non-linear mixed-effect modeling (NONMEM) was used as the
evaluation method.
Results: A total of 10 RCT studies, 1239 T2DM patients were included for
analysis, including eight studies of l-carnitine, one study of acetyl-l-carnitine, and
one study of propionyl-l-carnitine. The study found that l-carnitine could reduce the
Body Mass of T2DM patients. Based on only one study each for acetyl-l-carnitine
and propionyl-l-carnitine, no significant effects were found in acetyl-l-carnitine or
propionyl-l-carnitine. In addition, in order to achieve a plateau of efficacy (80% Emax),
2 g/day l-carnitine was required for at least 2 weeks.
Conclusions: Two g/day l-carnitine was required for at least 2 weeks to affect Body
Mass in T2DM patients, and no significant effects were found in acetyl-l-carnitine
or propionyl-l-carnitine.
Keywords: l-carnitine, acetyl-l-carnitine, propionyl-l-carnitine, Body Mass, type 2 diabetes mellitus
HIGHLIGHTS
- The present study analyzed the effects of l-carnitine, acetyl-l-carnitine, and propionyl-l-carnitine
on Body Mass in T2DM patients.
- L-carnitine could reduce the Body Mass of T2DM patients, in which 2 g/day l-carnitine was
required for at least 2 weeks.
- No significant effects on Body Mass were found from acetyl-l-carnitine or propionyl-l-carnitine
in T2DM patients.
Wang et al. Carnitine Effects on BMI in T2DM
INTRODUCTION
Type 2 diabetes mellitus (T2DM), a chronic degenerative disease
where the pancreas cannot produce enough insulin and/or
the insulin produced is inefficient, causing hyperglycemia, is
a major health problem and one of the top 10 causes of
mortality worldwide (1). According to the International Diabetes
Federation (IDF) (2019), 9.3% of adults around the world,
amount to 463 million people, have T2DM (1). This number
is expected to increase increase to 700 million people by 2045,
which is equivalent to 10.90% of the adult population worldwide
(1). In addition, T2DM is also an important risk factor for chronic
kidney disease, cardiovascular disease, and mortality (2).
From a clinical point of view, T2DM patients are often
accompanied by obesity, atherosclerotic disease, dyslipidemia,
and hypertension (3,4), in which more than 50% of T2DM
patients have been reported to be obese (3,5). Overweight or
obesity in T2DM can increase the cardiovascular disease risk
and further increase the risk of death, which are important
determinants of the prognosis in T2DM patients (5,6). Therefore,
intensive therapy for T2DM patients with overweight or obesity
is crucial (2).
At present, many drugs have been used to control blood
glucose and Body Mass in T2DM patients, among which Wang et
al. report the quantitative efficacy of l-carnitine supplementation
on glycemic control in T2DM patients (7). However, the effects
of l-carnitine, as well as its other forms of existence, acetyl-
l-carnitine, and propionyl-l-carnitine on Body Mass in T2DM
patients are still unclear. The present study is to explore the
effects of l-carnitine, acetyl-l-carnitine, and propionyl-l-carnitine
on Body Mass in T2DM patients.
METHODS
Literature Search and Data Extraction
We searched and extracted the Pubmed database (https://
pubmed.ncbi.nlm.nih.gov/) with the deadline of April 2021.
Only English publications were included. The terms “l-carnitine,
“acetyl-l-carnitine, “propionyl-l-carnitine,” and “type 2 diabetes
mellitus” were used in the present search strategy. Inclusion
criteria included: (I) randomized controlled trial (RCT), (II)
with Body Mass Index (BMI) information, (III) exact dose
and duration of l-carnitine, acetyl-l-carnitine, and propionyl-l-
carnitine. Source, country, grouping, sample size, age, duration of
treatment et al were extracted from the above-included studies.
In order to eliminate the potential baseline effect, the efficacy
of l-carnitine, acetyl-l-carnitine, and propionyl-l-carnitine were
evaluated using BMI change rate from the baseline value. The
Formula (1) was as follows:
E% =EtEb
Eb
×100% (1)
Et, the value of BMI at time t; Eb, the value of BMI at baseline.
Model Establishment
The Emax model was used to evaluate the effects of l-carnitine,
acetyl-l-carnitine or propionyl-l-carnitine on Body Mass in
T2DM patients. In addition, in order to acquire the actual effects
on BMI from l-carnitine, acetyl-l-carnitine, and propionyl-l-
carnitine, the control effects need to be subtracted from the sum
effects. The Formulas (2) and (3) were as follows:
ED,i,j =EI,i,j EC,i,j (2)
ED,i,j =Emax, i, j ×Time
ET50, i, j +Time +εi, j
qNi, j
100
(3)
EI,i,j, the sum effects on BMI from l-carnitine, acetyl-l-carnitine
or propionyl-l-carnitine, including actual effects and control
effects; ED,i,j, the actual effects on BMI; EC,i,j , the control effects on
BMI; i, different studies; j, the time point of every study; Emax, the
maximal effects on BMI; ET50, the treatment duration to reach
half of the maximal effects on BMI; εi,j, the residual error of study
i with j time; Ni,j, the sample size in study i with time point j. εi,j
was weighted by sample size, assumed to be normally distributed,
with a mean of 0 and variance of σ2/(Ni,j/100).
The inter-study variability was described by exponential error
or additive error models. The Formulas (4)–(7) were as follows:
Emax,i,j =Emax ×exp(η1,i) (4)
ET50,i,j =ET50 ×exp(η2,i) (5)
Emax,i,j =Emax +η1,i (6)
ET50,i,j =ET50 +η2,i (7)
η1,i,η2,i were the inter-study variabilities, when available, they
would be added into Emax, and ET50 , respectively. η1,i,η2,i
were assumed to be normally distributed, with a mean of 0 and
variance of ω1,i2,ω2,i 2, respectively.
In addition, continuous covariates and categorical covariates
were evaluated by Formulas (8)–(9) and (10):
Pp=PT+(COV COVm)·θc(8)
Pp=PT×(COV/COVm)θc(9)
Pp=PT+COV ×θc(10)
Pp, the parameter for a patient with a covariate value of COV;
PT, the typical value of the parameter; COV, covariate; COVm,
the median value of covariable in the population. θc, a correction
coefficient of the covariate to the model parameter.
The model development was done using non-linear mixed-
effect modeling (NONMEM, edition 7, ICON Development
Solutions, Ellicott City, MD, USA). When a basic model was
built, potential covariates were considered for adding into Emax.
The change of objective function value (OFV) was used as the
covariate inclusion criteria. When the decrease of OFV was >3.84
(χ2,α=0.05, d.f. =1), it was considered sufficient for inclusion.
When the increase of OFV was >6.63 (χ2,α=0.01, d.f. =1), it
was considered sufficient for significance in the final model (8).
Model Validation and Prediction
The goodness-of-fit plots of the model (individual predictions
vs. observations), distribution of conditional weighted residuals
(CWRES) for the model (density vs. CWRES, and quantiles
Frontiers in Nutrition | www.frontiersin.org 2November 2021 | Volume 8 | Article 748075
Wang et al. Carnitine Effects on BMI in T2DM
of CWRES vs. quantiles of normal), and individual plots
from different studies were used to estimate the final model.
Prediction-corrected visual predictive check (VPC) plots were
FIGURE 1 | Overview of the strategy for literature review.
used to assess the predictive performance of the final model.
In addition, the medians and 2.5th97.5th percentiles of the
results from bootstrap (Simulation, n=1,000) were used to
compare with final model parameters. The efficacy prediction of
l-carnitine on BMI in T2DM patients was simulated by the Monte
Carlo method.
RESULTS
Included Studies
Figure 1 was the retrieval process and a total of 10 RCT
studies, comprising 1,239 T2DM patients were included for
analysis, including 8 studies of l-carnitine (916), 1 study of
acetyl-l-carnitine (17), and 1 study of propionyl-l-carnitine (18).
The dosages of l-carnitine, acetyl-l-carnitine, and propionyl-l-
carnitine were 2–3, 2, and 2 g/day, respectively, in the included
studies, and the details were shown in Table 1, and part of
the literature was retrieved from the previous study (7). The
risk of bias analysis was shown in Figure 2. As both acetyl-l-
carnitine, and propionyl-l-carnitine had only 1 study, model-
based meta-analysis (MBMA) could not be performed at this
time for them. Further analysis found that no significant effects
on BMI in acetyl-l-carnitine or propionyl-l-carnitine in T2DM
patients. Therefore, the following MBMA analysis was mainly
aimed at l-carnitine.
Modeling and Validation
The actual drug effects of l-carnitine on BMI in T2DM patients
is shown in Table 2, the Emax of l-carnitine on BMI in T2DM
patients was 1.51% and the ET50 of l-carnitine on BMI
in T2DM patients was 0.5 weeks. In addition, no covariate
TABLE 1 | Included randomized controlled studies.
Study Country Group Sample size Age Duration
Intervention Control Intervention Control Intervention Control
El-Sheikh
et al. (16)
Egypt 2 g/day L-carnitine +4 mg/day
glimepiride
4 mg/day
glimepiride
31 27 50.9 ±8.6 50.3 ±8.8 6 months
Derosa et al.
(14)
Italy 2 g/day L-carnitine +360 mg/day
orlistat
360 mg/day
orlistat
132 126 51.0 ±4.0 53.0 ±6.0 12 months
Derosa et al.
(15)
Italy 2 g/day L-carnitine +10 mg/day
sibutramine
10 mg/day
sibutramine
129 125 54.0 ±5.0 51.0 ±4.0 12 months
Malaguarnera
et al. (13)
Italy 2 g/day L-carnitine +20 mg/day
simvastatin
20 mg/day
simvastatin
40 40 47.0 ±13.0 45.0 ±12.0 12 weeks
Malaguarnera
et al. (12)
Italy 2 g/day L-carnitine +placebo placebo 41 40 49.0 ±13.0 48.0 ±11.0 3 months
Galvano et al.
(11)
Italy 2 g/day L-carnitine +20 mg/day
simvastatin
20 mg/day
simvastatin
38 37 52.1 ±8.1 51.4 ±7.6 4 months
Derosa et al.
(10)
Italy 2 g/day L-carnitine +Placebo Placebo 46 48 52.0 ±6.0 50.0 ±7.0 6 months
Liang et al. (9) China 3 g/day L-carnitine +Placebo Placebo 23 23 59.4 ±1.7 57.9 ±2.6 12 weeks
Parvanova
et al. (17)
Italy 2 g/day Acetyl-L-
carnitine
+Placebo Placebo 109 110 64.9 ±7.7 64.6 ±7.5 6 months
Santo et al.
(18)
Italy 2 g/day
Propionyl-L-carnitine
+Placebo Placebo 37 37 61.75 ±3.03 61.26 ±1.6 12 months
Part of the literature was retrieved from the previous study (7).
Frontiers in Nutrition | www.frontiersin.org 3November 2021 | Volume 8 | Article 748075
Wang et al. Carnitine Effects on BMI in T2DM
FIGURE 2 | Risk of bias analysis.
TABLE 2 | Parameter estimates of final model and 95% confidential interval.
Parameter Estimate Simulation (n=1,000) Bias (%)
Median 95% confidence interval
Emax, % 1.51 1.51 [8.82, 0.62] 0
ET50, week 0.5 0.5 [0.5, 37.2] 0
ωEmax 1.345 1.200 [0.003, 6.982] 10.781
ωET50 0.003 0.003 [0.003, 9.798] 0
ε0.414 0.415 [0.159, 0.789] 0.242
95% confidential interval was showed with 2.5th, 97.5th percentile; Emax was the maximal
effects; ET50 was the treatment duration to reach half of Emax;ωEmax was the inter-study
variability of Emax;ωET 50 was the inter-study variability of ET50;εwas the residual error;
Bias =(Median-Estimate)/Estimate ×100%.
(in particular dosage) was incorporated into the Emax model,
showing there was no significant dose-dependence from l-
carnitine efficacy on BMI in T2DM patients in the present study.
The Emax model of l-carnitine on BMI in T2DM patients was
shown in Formulas (11):
E=1.51% ×Time
0.5 +Time (11)
E, efficacy of l-carnitine on BMI; Time, l-carnitine
treatment duration.
The visual inspection of routine diagnostic plots, and
individual predictions vs. observations, are shown in Figure 3A.
The distribution of CWRES for model (density vs. CWRES,
and quantilies of CWRES vs. quantiles of normal) are shown
in Figures 3B,C. Individual plots from different studies are
shown in Figure 3D. As we could see, there were good linear
relationships between individual predictions and observations,
and individual plots were also consistent meaning the good fitting
of the final models. At the same time, the distribution of the
model also satisfied the normal distribution.
The VPC plots are shown in Figure 4, and most observed
data were included in the 95% prediction intervals produced
by simulation data, which shows the predictive power of the
final models.
Prediction
We also simulated the curve of the final model for the effect of
l-carnitine on BMI via the Monte Carlo method. The trend of
the efficacy of l-carnitine on BMI in T2DM patients is shown
in Figure 5. As we could see from the curve, the efficacy of l-
carnitine on BMI at 0.5 weeks was 50% of the Emax, at 2 weeks
was 80% of the Emax (plateau stage), at 4.5 weeks was 90% of
the Emax, at 9.5 weeks was 95% of the Emax . In the current study,
the dose range was 2–3 g/day and there was no significant dose-
dependence from l-carnitine efficacy on BMI in T2DM patients,
so the lower dose of 2 g/day was selected as recommended dose.
In addition, in order to achieve a plateau of efficacy (80% Emax),
2 g/day l-carnitine was required for at least 2 weeks.
DISCUSSION
Carnitine is derived from amino acids and is found in almost
all cells in the body (19). Its name comes from the Latin
carnus, meaning meat, because the compound is extracted
from meat (19). Carnitine is a generic term, which includes l-
carnitine, acetyl-l-carnitine, and propionyl-l-carnitine (20). L-
carnitine plays an important role in energy metabolism (21).
It transfers long-chain fatty acids to cell mitochondria for
oxidation, which produces energy needed by the body (21,
22). It also transports harmful substances out of the organelle,
preventing them from accumulating in the cell (21). Because
of these functions, carnitine is found in high concentrations in
skeletal muscle and cardiac muscle cells, which allow them to
use fatty acids as an energy source (20). For most people, the
body can make enough to meet its needs, but for some people,
because of genetic or pharmaceutical reasons, the body cannot
produce enough, it is, therefore, an essential nutrient for these
individuals (23).
As is well-known, l-carnitine can adjust many events,
such as metabolism of glucose and fatty acids, and has the
Frontiers in Nutrition | www.frontiersin.org 4November 2021 | Volume 8 | Article 748075
Wang et al. Carnitine Effects on BMI in T2DM
FIGURE 3 | Model evaluation. (A) individual predictions vs. observations for the model from the effect of l-carnitine on BMI. (B) distribution of conditional weighted
residuals (CWRES) for model (density vs. CWRES). (C) distribution of CWRES for model (quantiles of CWRES vs. quantiles of normal). (D) individual plots for the
model from the effect of l-carnitine on BMI.
FIGURE 4 | Visual predictive check of the model from the l-carnitine effect on
BMI. Median, 2.5% CI and 97.5% CI were simulated by Monte Carlo (n=
1,000); CI, confidence interval; From a to h were studies come form El-Sheikh
et al. (16), Derosa et al. (14), Derosa et al. (15), Malaguarnera et al. (13),
Malaguarnera et al. (12), Galvano et al. (11), Derosa et al. (10), Liang et al. (9),
respectively.
potential to protect these cellular events in several manners
including decreasing the production of reactive oxygen species
at different points and maintaining mitochondrial functions
FIGURE 5 | Model prediction.
(24). In addition, it has been reported that l-carnitine had
many important pharmacological actions (2431), for example,
l-carnitine has a potential therapeutic effect in treating insulin
resistance (32). It is also reported that l-carnitine can improve
glycemia in T2DM patients (33). Wang et al.’s report provides
valuable quantitative information for the efficacy of l-carnitine
supplementation on glycemic control in T2DM patients (7).
Frontiers in Nutrition | www.frontiersin.org 5November 2021 | Volume 8 | Article 748075
Wang et al. Carnitine Effects on BMI in T2DM
They find that for the efficacy of l-carnitine on fasting plasma
glucose (FPG), 2 g/day l-carnitine is required for at least 36.1
weeks; For the efficacy of l-carnitine on glycated hemoglobin
(HbA1c), 2 g/day l-carnitine is required for at least 106 weeks
(7). However, the effects of l-carnitine, as well as its other
forms of existence, acetyl-l-carnitine, and propionyl-l-carnitine
on Body Mass in T2DM patients are still unclear. The purpose
of this study is to explore the effects of l-carnitine, acetyl-l-
carnitine, and propionyl-l-carnitine on Body Mass in T2DM
patients by MBMA.
In the present study, a total of 10 RCT studies comprising
1,239 T2DM patients were included for analysis, including 8
studies of l-carnitine (916), 1 study of acetyl-l-carnitine (17),
and 1 study of propionyl-l-carnitine (18). The dosages of l-
carnitine, acetyl-l-carnitine, and propionyl-l-carnitine were 2–
3, 2, and 2 g/day, respectively, in the included studies. Of
course, when investigating the efficacy of a drug on Body Mass,
important factors should be stable such as diet, antiglycemic
drugs, and duration of T2DM. Fortunately, since our study
was from RCTs, conditions in the intervention group and the
control group were similar in each study. In this way, the control
group effects were deducted from the intervention group, and
the actual l-carnitine drug effects were obtained. In addition,
we also considered the impact of various indicators in different
studies on baseline values. In addition, as for both acetyl-l-
carnitine, and propionyl-l-carnitine had only 1 study, MBMA
analysis could not be performed at this time for them. Further
analysis found no significant effects on BMI in acetyl-l-carnitine
or propionyl-l-carnitine in T2DM patients.
In further analysis of the effects of l-carnitine on Body Mass
in T2DM patients, we found the Emax of l-carnitine on BMI
in T2DM patients was 1.51% and the ET50 of l-carnitine
on BMI in T2DM patients was 0.5 weeks. In addition, no
covariate (in particular dosage) was incorporated into the Emax
model, showing there was no significant dose-dependence from l-
carnitine efficacy on BMI in T2DM patients. In the current study,
the dose range was 2–3 g/day, there was no significant dose-
dependence from l-carnitine efficacy on BMI in T2DM patients,
so the lower dose of 2 g/day was selected as recommended
dose. In addition, in order to achieve a plateau of efficacy (80%
Emax), 2 g/day l-carnitine was required for at least 2 weeks.
From the current view, l-carnitine could play an important
role in glucose metabolism and increase energy expenditure,
meanwhile, l-carnitine had a role in lipid metabolism as well
(3436). For these two reasons, l-carnitine helps Body Mass
loss by increasing energy expenditure (36). However, this
study had some limitations. The number of studies currently
included was limited, and additional studies were needed in
the future.
CONCLUSIONS
Two gram per day l-carnitine was required for at least 2 weeks
to affect Body Mass in T2DM patients, and no significant effects
were found in acetyl-l-carnitine or propionyl-l-carnitine.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
AUTHOR CONTRIBUTIONS
D-DW, S-MH, and Y-MW conceived and designed the study. D-
DW, T-YW, YY, and S-MH collected and analyzed data. D-DW
wrote the paper. S-MH reviewed and edited the manuscript. All
authors read and approved the final manuscript.
FUNDING
This work was supported by the Initializing Fund of Xuzhou
Medical University (No. RC20552111), the Fusion Innovation
Project of Xuzhou Medical University (No. XYRHCX2021011),
the Xuzhou Special fund for promoting scientific and
technological innovation (No. KC21257), the Suzhou
Science & Technology Town Hospital pre-research fund
project (No. 2019Y01), the Suzhou Science and Technology
Development Plan Project (No. S YSD2019076), and the Jiangsu
Pharmaceutical Society-Tianqing Hospital Pharmaceutical Fund
Project (No. Q202024).
REFERENCES
1. Zepeda-Pena AC, Gurrola-Diaz CM, Dominguez-Rosales JA, Garcia-Lopez
PM, Pizano-Andrade JC, Hernandez-Nazara ZH, et al. Effect of Lupinus
rotundiflorus gamma conglutin treatment on JNK1 gene expression and
protein activation in a rat model of type 2 diabetes. Pharm Biol. (2021)
59:374–80. doi: 10.1080/13880209.2021.1893757
2. Uneda K, Kawai Y, Yamada T, Kinguchi S, Azushima K, Kanaoka T,
et al. Systematic review and meta-analysis for prevention of cardiovascular
complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese
diabetic patients. Sci Rep. (2021) 11:10166. doi: 10.1038/s41598-021-89620-7
3. Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, et al. Prevalence and
co-prevalence of comorbidities among patients with type 2 diabetes mellitus.
Curr Med Res Opin. (2016) 32:1243–52. doi: 10.1185/03007995.2016.1168291
4. Gonzalez-Muniesa P, Martinez-Gonzalez MA, Hu FB, Despres JP,
Matsuzawa Y, Loos RJF, et al. Obesity. Nat Rev Dis Primers. (2017)
3:17034. doi: 10.1038/nrdp.2017.34
5. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular
disease in type 2 diabetes: a systematic literature review of scientific
evidence from across the world in 2007-2017. Cardiovasc Diabetol. (2018)
17:83. doi: 10.1186/s12933-018-0728-6
6. American Diabetes Association. 8. Obesity management for the treatment of
type 2 diabetes: standards of medical care in diabetes-2020. Diabetes Care.
(2020) 43(Suppl 1):S89–97. doi: 10.2337/dc20-S008
7. Wang DD, Mao YZ, He SM, Yang Y, Chen X. Quantitative efficacy
of L-carnitine supplementation on glycemic control in type 2
diabetes mellitus patients. Expert Rev Clin Pharmacol. (2021)
1–8. doi: 10.1080/17512433.2021.1917381
8. Wang DD, Mao YZ, He SM, Chen X. Analysis of time course and dose effect
from metformin on Body Mass Index in children and adolescents. Front
Pharmacol. (2021) 12:611480. doi: 10.3389/fphar.2021.611480
9. Liang Y, Li Y, Shan J, Yu B, Ho Z. The effects of oral L-carnitine treatment on
blood lipid metabolism and the body fat content in the diabetic patient. Asia
Pac J Clin Nutr. (1998) 7:192–5.
Frontiers in Nutrition | www.frontiersin.org 6November 2021 | Volume 8 | Article 748075
Wang et al. Carnitine Effects on BMI in T2DM
10. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The
effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic
patients with type 2 diabetes mellitus. Clin Ther. (2003) 25:1429–
39. doi: 10.1016/S0149-2918(03)80130-3
11. Galvano F, Li Volti G, Malaguarnera M, Avitabile T, Antic T, Vacante M, et al.
Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and
apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother. (2009)
10:1875–82. doi: 10.1517/14656560903081745
12. Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri
L, Motta M. L-Carnitine supplementation reduces oxidized LDL
cholesterol in patients with diabetes. Am J Clin Nutr. (2009)
89:71–6. doi: 10.3945/ajcn.2008.26251
13. Malaguarnera M, Vacante M, Motta M, Malaguarnera M, Li Volti G, Galvano
F. Effect of L-carnitine on the size of low-density lipoprotein particles in
type 2 diabetes mellitus patients treated with simvastatin. Metabolism. (2009)
58:1618–23. doi: 10.1016/j.metabol.2009.05.014
14. Derosa G, Maffioli P, Ferrari I, D’Angelo A, Fogari E, Palumbo I,
et al. Comparison between orlistat plus l-carnitine and orlistat alone on
inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol.
(2011) 25:642–51. doi: 10.1111/j.1472-8206.2010.00888.x
15. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, et al. Effects
of combination of sibutramine and L-carnitine compared with sibutramine
monotherapy on inflammatory parameters in diabetic patients. Metabolism.
(2011) 60:421–9. doi: 10.1016/j.metabol.2010.03.010
16. El-Sheikh HM, El-Haggar SM, Elbedewy TA. Comparative study to evaluate
the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin
resistance in type 2 diabetic patients. Diabetes Metab Syndr. (2019) 13:167–
73. doi: 10.1016/j.dsx.2018.08.035
17. Parvanova A, Trillini M, Podesta MA, Iliev IP, Aparicio C, Perna A,
et al. blood pressure and metabolic effects of acetyl-l-carnitine in type 2
diabetes: DIABASI randomized controlled trial. J Endocr Soc. (2018) 2:420–
36. doi: 10.1210/js.2017-00426
18. Santo SS, Sergio N, Luigi DP, Giuseppe M, Margherita F, Gea OC,
et al. Effect of PLC on functional parameters and oxidative profile in
type 2 diabetes-associated PAD. Diabetes Res Clin Pract. (2006) 72:231–
7. doi: 10.1016/j.diabres.2005.10.007
19. Dahash BA, Sankararaman S. Carnitine Deficiency. Treasure Island, FL:
StatPearls (2021).
20. Jiang Q, Wang C, Xue C, Xue L, Wang M, Li C, et al. Changes in
the levels of l-carnitine, acetyl-l-carnitine and propionyl-l-carnitine
are involved in perfluorooctanoic acid induced developmental
cardiotoxicity in chicken embryo. Environ Toxicol Pharmacol. (2016)
48:116–24. doi: 10.1016/j.etap.2016.10.017
21. Bota AB, Simmons JG, DiBattista A, Wilson K. Carnitine in alcohol
use disorders: a scoping review. Alcohol Clin Exp Res. (2021) 45:666–
74. doi: 10.1111/acer.14568
22. Longo N, Frigeni M, Pasquali M. Carnitine transport and
fatty acid oxidation. Biochim Biophys Acta. (2016) 1863:2422–
35. doi: 10.1016/j.bbamcr.2016.01.023
23. Bene J, Hadzsiev K, Melegh B. Role of carnitine and its derivatives in the
development and management of type 2 diabetes. Nutr Diabetes. (2018)
8:8. doi: 10.1038/s41387-018-0017-1
24. Modanloo M, Shokrzadeh M. Analyzing mitochondrial dysfunction, oxidative
stress, and apoptosis: potential role of l-carnitine. Iran J Kidney Dis.
(2019) 13:74–86.
25. Jiang Q, Jiang G, Shi KQ, Cai H, Wang YX, Zheng MH. Oral acetyl-L-carnitine
treatment in hepatic encephalopathy: view of evidence-based medicine. Ann
Hepatol. (2013) 12:803–9. doi: 10.1016/S1665-2681(19)31323-7
26. Ribas GS, Vargas CR, Wajner M. L-carnitine supplementation as a potential
antioxidant therapy for inherited neurometabolic disorders. Gene. (2014)
533:469–76. doi: 10.1016/j.gene.2013.10.017
27. Khalatbari-Soltani S, Tabibi H. Inflammation and L-carnitine therapy
in hemodialysis patients: a review. Clin Exp Nephrol. (2015) 19:331–
5. doi: 10.1007/s10157-014-1061-3
28. Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and
safety of l-carnitine treatment for chronic heart failure: a meta-
analysis of randomized controlled trials. Biomed Res Int. (2017)
2017:6274854. doi: 10.1155/2017/6274854
29. Askarpour M, Hadi A, Dehghani Kari Bozorg A, Sadeghi O, Sheikhi
A, Kazemi M, et al. Effects of L-carnitine supplementation on blood
pressure: a systematic review and meta-analysis of randomized controlled
trials. J Hum Hypertens. (2019) 33:725–34. doi: 10.1038/s41371-019-
0248-1
30. Askarpour M, Hadi A, Symonds ME, Miraghajani M, Omid S, Sheikhi
A, et al. Efficacy of l-carnitine supplementation for management of
blood lipids: a systematic review and dose-response meta-analysis of
randomized controlled trials. Nutr Metab Cardiovasc Dis. (2019) 29:1151–
67. doi: 10.1016/j.numecd.2019.07.012
31. Askarpour M, Hadi A, Miraghajani M, Symonds ME, Sheikhi A, Ghaedi
E. Beneficial effects of l-carnitine supplementation for weight management
in overweight and obese adults: an updated systematic review and dose-
response meta-analysis of randomized controlled trials. Pharmacol Res. (2020)
151:104554. doi: 10.1016/j.phrs.2019.104554
32. Xu Y, Jiang W, Chen G, Zhu W, Ding W, Ge Z, et al. L-carnitine treatment of
insulin resistance: a systematic review and meta-analysis. Adv Clin Exp Med.
(2017) 26:333–8. doi: 10.17219/acem/61609
33. Vidal-Casariego A, Burgos-Pelaez R, Martinez-Faedo C, Calvo-Gracia F,
Valero-Zanuy MA, Luengo-Perez LM, et al. Metabolic effects of L-
carnitine on type 2 diabetes mellitus: systematic review and meta-analysis.
Exp Clin Endocrinol Diabetes. (2013) 121:234–8. doi: 10.1055/s-0033-
1333688
34. Wall BT, Stephens FB, Constantin-Teodosiu D, Marimuthu K,
Macdonald IA, Greenhaff PL. Chronic oral ingestion of L-carnitine
and carbohydrate increases muscle carnitine content and alters muscle
fuel metabolism during exercise in humans. J Physiol. (2011) 589(Pt
4):963–73. doi: 10.1113/jphysiol.2010.201343
35. Kim JH, Pan JH, Lee ES, Kim YJ. L-Carnitine enhances exercise endurance
capacity by promoting muscle oxidative metabolism in mice. Biochem Biophys
Res Commun. (2015) 464:568–73. doi: 10.1016/j.bbrc.2015.07.009
36. Pooyandjoo M, Nouhi M, Shab-Bidar S, Djafarian K, Olyaeemanesh A. The
effect of (L-)carnitine on weight loss in adults: a systematic review and
meta-analysis of randomized controlled trials. Obes Rev. (2016) 17:970–
6. doi: 10.1111/obr.12436
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Wang, Wang, Yang, He and Wang. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Nutrition | www.frontiersin.org 7November 2021 | Volume 8 | Article 748075
... Furthermore, the non-linear dose-response showed an association between L-carnitine supplementation and body weight, indicating a decreasing trend of body weight in durations more than 25 weeks. A metaanalysis of 10 RCT studies done by Wang in 2021 showed that 2 g/day of L-carnitine for at least 2 weeks is required to lower BMI in T2D patients [98]. Another meta-analysis done in 2019 consisting of 37 RCTs, revealed that L-carnitine supplementation significantly decreases body weight, BMI, and fat mass without any effect on BFP. ...
Article
Full-text available
Aims L-carnitine plays a role related to cardiometabolic factors, but its effectiveness and safety in CVD are still unknown. We aim to assess the effect of L-carnitine supplementation on CVD risk factors. Methods A systematic literature search was conducted in PubMed, Web of Science, and Scopus until October 2022. The main outcomes were lipid profiles, anthropometric parameters, insulin resistance, serum glucose levels, leptin, blood pressure, and inflammatory markers. The pooled weighted mean difference (WMD) was calculated using a random-effects model. Results We included the 21 RCTs (n = 2900) with 21 effect sizes in this study. L-carnitine supplementation had a significant effect on TG (WMD = − 13.50 mg/dl, p = 0.039), LDL (WMD = − 12.66 mg/dl, p < 0.001), FBG (WMD = − 6.24 mg/dl, p = 0.001), HbA1c (WMD = -0.37%, p = 0.013) HOMA-IR (WMD = -0.72, p = 0.038 (, CRP (WMD = − 0.07 mg/dl, P = 0.037), TNF-α (WMD = − 1.39 pg/ml, p = 0.033), weight (WMD = − 1.58 kg, p = 0.001 (, BMI (WMD = − 0.28 kg/m², p = 0.017(, BFP (WMD = − 1.83, p < 0.001) and leptin (WMD = − 2.21 ng/ml, p = 0.003 (in intervention, compared to the placebo group, in the pooled analysis. Conclusions This meta-analysis demonstrated that administration of L-carnitine in diabetic and glucose intolerance patients can significantly reduce TG, LDL-C, FBG, HbA1c, HOMA-IR, CRP, TNF-α, weight, BMI, BFP, and leptin levels. PROSPERO registration code: CRD42022366992.
... As L-carnitine converts fat into energy, it is very popular among bodybuilders and athletes as a weight loss supplement. A review study of 10 RCTs including 1239 type-2 diabetic patients, reported that 2-3 g/day of L-carnitine was required for at least 12 weeks to reduce body mass index significantly (Wang et al., 2021). A comparative study by Kalpana and Aruna (2012), concluded that L-carnitine (1g/day) with a carnitine-rich diet and exercise helped obese adults in the intervention group to lose weight significantly compared to the placebo group. ...
Article
Full-text available
Metabolic syndrome and obesity are two major determinants for many noncommunicable diseases, such as non-alcoholic fatty liver disease, diabetes and cancer. Lifestyle modification, dietary interventions and weight loss are found to be efficacious remedies. In alternative medications, many functional foods and nutraceuticals have contributed significantly until now. L-carnitine is one of them, which is gaining importance as an ergogenic aid among athletes for muscle building and energy production. It has supported many medical therapies for the treatment of liver, heart and other diseases. It is available in pharmacological form as well as found naturally in various animal and plant foods. This review of recent clinical trials was aimed to show the efficacy and safety of carnitine supplements available in medicine form or food sources. The clinical outcome of various studies included for analysis indicated that when L-carnitine tablets (0.5 g-2 g) were given to intervention group patients of various diseases, for about 2-6 months duration, helped in a significant reduction of liver enzymes, blood sugar and bodyweight compared to controls. Furthermore, a few randomized clinical trials in which carnitine-rich low-fat animal foods on the Mediterranean diet were given in their recommended doses to patients, provided therapeutic benefits. The beneficial effects of lysine and methioninerich foods through the Green Mediterranean diet on vegetarians for endogenous carnitine synthesis have been reported. Large-scale clinical trials, including natural foods that would be cost-effective, long-term and safe for vegetarians, are warranted.
... Additionally, damaging to mitochondria, oxidative stress impairs mitochondrial -oxidation, which causes hepatocytes to accumulate fatty acids and causes hepatic damage such hepatic steatosis. Due to its role in fatty acidoxidation and the conversion of lipids into energy in the mitochondria, treating animals with L-carnitine may have a reversible effect on the formation of steatosis, this might be how L-carnitine protects against the potentially harmful effects of cytarabine (28,29). ...
Article
Full-text available
Hepatotoxicity is a common clinical manifestation associated with a wide range of anticancer therapies. Because of the inherent toxicity of anticancer therapies, oncologists must maintain a broad understanding of their effects on the body, including the liver. Therefore, the study was conducted to examine the effects of two doses of L-carnitine on damaged liver as a result of giving cytarabine. Twenty-four male rats were used in the experiment. The rats divided to four group each group with six rats,the first group injected normal saline intraperitoneally and set as control group(G1), the second group injected cytarabine 25 mg/kg/bw, intraperitoneally and set as (G2), the third group injected cytarabine 25 mg/kg/bw and 50 mg/kg/bw, L-carnitine intraperitoneally and set as (G3), the fourth group injected cytarabine 25 mg/kg/bw and 300 mg/kg/bw, L-carnitine intraperitoneally and set as (G4), the study showed that use of L-carnitine reduced the harmful effect of cytarabine in the body when compared to other groups that were injected only with cytarabine at level of (p-value <0.05).The rats treated with L-carnitine have shown significant elevation in CAT and SOD and reduction of the level of MDA.
... The destruction of membrane lipids and the end-products of such lipid peroxidation reactions are especially dangerous for the viability of cells, even tissues. Enzymatic (catalase, superoxide dismutase), since lipid peroxidation is a self-propagating chain-reaction, the initial oxidation of only a few lipid molecules can result in significant tissue damage (40,41). ...
Article
Full-text available
Hepatotoxicity is a common clinical manifestation associated with a wide range of anticancer therapies. Because of the inherent toxicity of anticancer therapies, oncologists must maintain a broad understanding of their effects on the body, including the liver.Therefore, the study was conducted to examine the effects of two doses of L-carnitine on damaged liver as a result of giving cytarabine. Twenty-four male rat were used in the experiment. The rats divided to four group each group with six rats,the first group injected normal salineintraperitoneally and set as control group(G1),the second group injected cytarabine 25 mg/kg/bw intraperitoneally and set as (G2), the third injected cytarabine 25 mg/kg/bw and 50 mg /kg/bw L-carnitine intraperitoneally and set as (G3), the third injected cytarabine 25 mg/kg/bw and 300mg/kg/bw L-carnitine Intraperitoneally and set as(G4), the study showed that use of L-carnitine reduced the harmful effect of cytarabinein the body when compared to the group that was injected only with cytarabineat level of (p-value <0.05). ALT show a significant increase in G2 when compared to other groups the mean value was (104±7.697, 134.66±13.08, 105.66±5.89, 94.33±3.5) for groups: control, cytarabine,50mg/kg/bw & 300mg/kg/bw ofL-carnitine respectively;
Article
This study aims to investigate the action mechanism of guaijaverin on pancreatic lipase from multiple perspectives and provide a theoretical basis for the search for new pancreatic lipase inhibitors. The inhibition of pancreatic lipase by guaijaverin was investigated through enzyme inhibition activity experiments, and the IC 50 was calculated to determine the type of inhibition of guaijaverin. The mechanism of action was studied by measuring fluorescence, ultraviolet spectra, and circular dichroism. Molecular docking technology was used to explore the binding situation. In addition, in vivo oral lipid tolerance tests in rats were carried out to investigate the inhibitory effect of guaijaverin on pancreatic lipase. Guaijaverin inhibited pancreatic lipase up to 90.63%, confirming its excellent inhibitory ability. The inhibition type was noncompetitive inhibition in reversible inhibition. The multispectral experiments indicated that its quenching type was static quenching and guaijaverin changed the microenvironment and spatial conformation of pancreatic lipase. The molecular docking results showed that the minimum binding energy between the two compounds was −6.96 kcal/mol. In vivo experiments demonstrated that guaijaverin inhibits pancreatic lipase by reducing TG uptake in the body. Guaijaverin has excellent inhibitory effects on pancreatic lipase and has the potential to function as a pancreatic lipase inhibitor.
Article
Full-text available
Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been shown to prevent CVD in T2DM patients. Additionally, the two drugs reduce body mass. However, it is unknown which drug is more effective at reducing the risk of CVD in such patients. We searched Medline, EMBASE, and Cochrane Library records to February 20, 2021 and performed a network meta-analysis to compare the efficacy with which the drugs reduced the risk of major adverse cardiovascular events (MACE). We included 102,728 patients in 12 studies containing data of obesity subgroup analyses. In T2DM patients with obesity, GLP-1 RAs significantly reduced the risk of MACE versus placebo (relative risk, RR [95% confidence interval, CI]: 0.88 [0.81–0.96]), whereas SGLT-2 inhibitors showed a tendency (RR [95% CI]: 0.91 [0.83–1.00]). In an indirect comparison, GLP-1 RAs were not associated with a significant difference in MACE compared with SGLT-2 inhibitors (RR [95% CI]: 0.97 [0.85–1.09]). Thus, GLP-1 RAs are effective at preventing MACE than placebo in T2DM patients with obesity, although further studies are warranted to conclude their superiority to SGLT-2 inhibitors.
Article
Full-text available
The purpose of this study was to analyze the time course and dose effect from metformin on body mass index (BMI) in children and adolescents by model-based meta-analysis (MBMA). Searching randomized controlled trial (RCT) studies of metformin on BMI in children and adolescents. The change rates of BMI from baseline values were used as indicator of evaluating metformin efficacy. A total of 18 RCT studies, 1,228 children and adolescents, were included for analysis, including patients with obesity, patients with type 1 diabetes mellitus, patients with nonalcoholic fatty liver, and patients with precocity. In order to achieve better effect of metformin on BMI in children and adolescents, the present study recommended that for patients with obesity, 1,000 mg/day metformin was required for at least 15.2 weeks and 60.8 weeks to achieve the plateau of metformin effect; for patients with type 1 diabetes mellitus, 1,000 mg/day metformin was required for at least 25.2 weeks and 100.8 weeks to achieve the plateau of metformin effect; for patients with nonalcoholic fatty liver, 1,000 mg/day metformin was required for at least 6.57 weeks and 26.28 weeks to achieve the plateau of metformin effect; for patients with precocity, 425 mg/day metformin was required for at least 12.4 weeks and 49.6 weeks to achieve the plateau of metformin effect. It was the first time to analyze the time course and dose effect from metformin on BMI and to recommend dosage and duration of treatment for metformin in children and adolescents with different disease types.
Article
Full-text available
Context Gamma conglutin (Cγ) from lupine species represents a potential complementary treatment for type 2 diabetes mellitus (T2DM) because of its hypoglycaemic effect. However, its underlying mechanism of action is not fully known. Objective To evaluate whether Cγ from Lupinus rotundiflorus M. E. Jones (Fabaceae) modulates c-Jun N-terminal kinase 1 (JNK1) expression and activation in a T2DM rat model. Materials and methods Gamma conglutin isolated from L. rotundiflorus seeds was characterized by SDS-PAGE. Fifteen Wistar rats with streptozotocin-induced T2DM (HG) were randomized into three groups (n = 5): vehicle administration (HG-Ctrl), oral treatment with Cγ (120 mg/kg/day) (HG-Lr) for one week, and treatment with metformin (300 mg/kg/day) (HG-Met); a healthy group (Ctrl, n = 5) was included as control. The levels of glucose and biomarkers of renal and hepatic function were measured pre- and post-treatment. Hepatic Jnk1 expression and phosphorylation of JNK1 were evaluated by qRT-PCR and western blot, respectively. Results Oral treatment with either Cγ or metformin reduced serum glucose level to 86.30 and 74.80 mg/dL, respectively (p ˂ 0.05), from the basal levels. Jnk1 expression was 0.65- and 0.54-fold lower (p ˂ 0.05) in the HG-Lr and HG-Met groups, respectively, than in HG-Ctrl. Treatment with Cγ decreased JNK1 phosphorylation. However, Cγ did not change the levels of kidney and liver biomarkers. Discussion and conclusions Treatment with Cγ from L. rotundiflorus inhibited Jnk1 expression, in vivo, suggesting JNK1 as a potential therapeutic target in diabetes and revealing one mechanism underlying the hypoglycaemic effect of lupine Cγ. Nevertheless, further studies are required.
Article
Full-text available
Recent studies in alcohol use disorders (AUDs) have demonstrated some connections between carnitine metabolism and the pathophysiology of the disease. In this scoping review, we aimed to collate and examine existing research available on carnitine metabolism and AUDs and develop hypotheses surrounding the role carnitine may play in AUD. A scoping review method was used to search electronic databases in September 2019. The database search terms used included “alcohol, alcoholism, alcohol abuse, alcohol consumption, alcohol drinking patterns, alcohol‐induced disorders, alcoholic intoxication, alcohol‐related disorders, binge drinking, Wernicke encephalopathy, acylcarnitine, acetyl‐l‐carnitine, acetylcarnitine, carnitine and palmitoylcarnitine.” The inclusion criteria included English language, human‐based, AUD diagnosis and measured blood or tissue carnitine or used carnitine as a treatment. Of 586 studies that were identified and screened, 65 underwent abstract review, and 41 were fully reviewed. Eighteen studies were ultimately included for analysis. Data were summarized in an electronic data extraction form. We found that there is limited literature available. Alcohol use appears to impact carnitine metabolism, most clearly in the setting of alcoholic cirrhosis. Six studies found carnitine to be increased in AUD, of which 5 were conducted in patients with alcoholic cirrhosis. Only 3 placebo‐controlled trials were identified and provide some support for the use of carnitine in AUD to decrease cravings, anhedonia, and withdrawal and improve cognition. The increase in plasma carnitine in alcoholic cirrhosis may be related to disordered fatty acid metabolism and oxidative stress that occurs in AUD. The multiple possible therapeutic effects carnitine could have on ethanol metabolism and the early evidence available for carnitine supplementation as a treatment for AUD provide a foundation for future randomized control trials of carnitine for treating AUD.
Article
Objectives This study aimed to explore the quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients using model-based meta-analysis (MBMA). Methods Literatures were retrieved from the public database and data from these trials were extracted. The quantitative efficacy of L-carnitine on fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) in type 2 diabetes mellitus patients were evaluated by maximal effect (Emax) models with nonlinear mixed effects modeling (NONMEM). Results In the model of FPG, Emax and treatment duration to reach half of the maximal effects (ET50) were -9.8% and 36.1 weeks, respectively. In the model of HbA1c, Emax and ET50 were -19.6% and 106 weeks, respectively. In addition, the durations for achieving 25%, 50%, 75%, 80%, and 90% Emax of L-carnitine on FPG were 13, 36.1, 118, 160, and 390 weeks, respectively. The durations for achieving 25%, 50%, 75%, 80%, and 90% Emax of L-carnitine on HbA1c were 38, 106, 334, 449, and 1058 weeks, respectively. Conclusions It was the first time to provide valuable quantitative information for efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients.
Article
The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Article
Despite preclinical studies demonstrating the efficacy of L-carnitine supplementation for weight management, findings in clinical setting are contradictory. Electronic bibliographical databases were systematically searched up to February 2019 with no limitation in language, including Scopus, PubMed, ISI Web of Science and Cochrane Library. Clinical trials registry platform were also searched. All randomized controlled trials (RCTs) which reported an effect of L-carnitine supplementation on obesity-related indices were included. Weighted mean difference (WMD) was estimated using a random-effect model (DerSimonian-Laird method). Eventually 43 eligible RCTs were included for quantitative analysis. Meta-analysis results revealed that L-carnitine supplementation significantly decreased weight (WMD: -1.129 kg, 95% CI: -1.590, -0.669; I2: 63.4), body mass index (BMI) (WMD: -0.359 kg/m2, 95% CI: -0.552, -0.167; I2:85.2) and fat mass (WMD: -1.158 kg, 95% CI: -1.763, -0.554, I2:15.5). However, L-carnitine supplementation did not change body fat percentage (WMD: -0.874 %, 95% CI: -1.890, 0.142, I2:98.2) or waist circumference (WMD: -0.883 mg/dl, 95% CI: -1.770, 0.004, I2:74.8). L-carnitine supplementation changed weight (r = -0.98) and BMI (r = -0.67) in a non-linear fashion based on carnitine dosage and BMI according to trial duration (r = -0.04). Interestingly subgroup analysis revealed that L-carnitine showed anti-obesity effects only in overweight and obese subjects; L-carnitine decreased weight, and BMI alone when combined with other lifestyle modifications. Anthropometric indexes were not changed following L-carnitine supplementation among patients' undergoing hemodialysis. Our study revealed that L-carnitine supplementation might have a positive effects in achieving an improved body weight and BMI especially in overweight and obese subjects.
Article
l-carnitine plays a fundamental biological role in the metabolism of lipids and may positively affect blood pressure by decreasing insulin resistance, although the latter remains less clear. We aimed to assess the effects of l-carnitine supplementation on systolic (SBP) and diastolic blood pressure (DBP). A search was conducted using databases of EMBASE, PubMed, Scopus, Cochrane Library, and ISI web of Science from inception to February 2019 without limitations in language. A meta-analysis was conducted on a total of ten eligible randomized controlled trials using a random-effects model to estimate the pooled effect sizes of l-carnitine supplementation on SBP and DBP levels. Results were expressed as weighted mean difference (WMD) and 95% confidence intervals (CI). l-carnitine supplementation decreased DBP (−1.162 mmHg, 95% CI: −2.020, −0.303, p = 0.008) without changing SBP levels (−0.085 mmHg, 95% CI: −1.455, 1.285, p = 0.903). Results of the subgroup analyses revealed l-carnitine supplementation decreased DBP levels in participants with overweight and obesity (−1.232 mmHg, 95% CI: −2.297, −0.167, p = 0.023) and with doses of <2 g/d (−1.639 mmHg, 95% CI: −3.038, −0.240, p = 0.022). No evidence of publication bias was observed about the effects of l-carnitine supplementation on SBP (p = 0.307) and DBP (p = 0.729), as evidenced by the results of the Egger’s test. In conclusion, l-carnitine supplementation decreased DBP without affecting SBP levels. Research is required to determine the molecular mechanism underlying the relationship between of l-carnitine on blood pressure.
Article
Background and aim: l-carnitine has an important role in fatty acid metabolism and could therefore act as an adjuvant agent in the improvement of dyslipidemia. The purpose of present systematic review and meta-analysis was to critically assess the efficacy of l-carnitine supplementation on lipid profiles. Methods and results: We performed a systematic search of all available randomized controlled trials (RCTs) in the following databases: Scopus, PubMed, ISI Web of Science, The Cochrane Library. Mean difference (MD) of any effect was calculated using a random-effects model. In total, there were 55 eligible RCTs included with 58 arms, and meta-analysis revealed that l-carnitine supplementation significantly reduced total cholesterol (TC) (56 arms-MD: -8.53 mg/dl, 95% CI: -13.46, -3.6, I2: 93%), low-density lipoprotein-cholesterol (LDL-C) (47 arms-MD: -5.48 mg/dl, 95% CI: -8.49, -2.47, I2: 94.5) and triglyceride (TG) (56 arms-MD: -9.44 mg/dl, 95% CI: -16.02, -2.87, I2: 91.8). It also increased high density lipoprotein-cholesterol (HDL-C) (51 arms-MD:1.64 mg/dl, 95% CI:0.54, 2.75, I2: 92.2). l-carnitine supplementation reduced TC in non-linear fashion based on dosage (r = 21.11). Meta-regression analysis indicated a linear relationship between dose of l-carnitine and absolute change in TC (p = 0.029) and LDL-C (p = 0.013). Subgroup analyses showed that l-carnitine supplementation did not change TC, LDL-C and TG in patients under hemodialysis treatment. Intravenous l-carnitine and lower doses (>2 g/day) had no effect on TC, LDL-C and triglycerides. Conclusion: l-carnitine supplementation at doses above 2 g/d has favorable effects on patients' lipid profiles, but is modulated on participant health and route of administration.